Publications by authors named "D D Holm"
Safety and efficacy of faecal microbiota transplantation in patients with acute uncomplicated diverticulitis: study protocol for a randomised placebo-controlled trial.
Therap Adv Gastroenterol
January 2025
Background: Little is known about the involvement of gut microbiota in the disease course of diverticulitis and the potential benefits of manipulating the gut milieu. We propose to conduct a randomised placebo-controlled feasibility trial of faecal microbiota transplantation (FMT) given as capsules to patients with acute uncomplicated diverticulitis.
Objectives: The objective is primarily to investigate the feasibility of clinical safety, explore efficacy associated with FMT in this patient population, and examine changes in patient-reported quality of life and the composition and function of the gut microbiota.
Background: Fecal Microbiota Transplant (FMT) is an effective treatment for recurring Clostridioides Difficile Infections (rCDI). FMT administered oral capsules (caFMT) offers several practical advantages to conventional liquid FMT. We began using caFMT in 2021 imported from an external institution.
View Article and Find Full Text PDFReview of Medical Adhesive Technology in the Context of Medical Adhesive-Related Skin Injury.
J Wound Ostomy Continence Nurs
September 2024
In clinical practice, a large variety of medical devices adhere to skin to perform their function. The repeated application and removal of these devices can lead to skin damage or medical adhesive-related skin injury. Awareness of this problem has increased in the past decade, and this adverse event can be prevented with appropriate selection of adhesive products and the appropriate techniques for application and removal.
View Article and Find Full Text PDFHumoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.
Front Immunol
September 2024
Article Synopsis
- This study investigates how patients with multiple sclerosis (MS) on anti-CD20 therapy respond to multiple doses of the BNT162b2 mRNA COVID-19 vaccine and the incidence of breakthrough infections.
- It found that the percentage of participants with antibodies increased significantly after the fourth vaccine dose, but a majority still experienced breakthrough infections during the study.
- The study concluded that while antibody levels increased post-vaccination, T-cell responses remained stable and were not affected by breakthrough infections.
Objectives: (Bbsl) and tick-borne encephalitis virus (TBEV) are tick-borne pathogens. This study aimed to investigate the seroprevalence of these pathogens in Danish blood donors.
Methods: A total of 1000 plasma samples equally distributed (n = 200) from all five Danish regions were analyzed.